Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03593239
Other study ID # PROT-00008 / v2.1
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date June 29, 2018
Est. completion date July 26, 2018

Study information

Verified date June 2021
Source Juul Labs, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A Ten Sequence, Open Label, Randomized Crossover Study Comparing Nicotine Pharmacokinetics of JUUL 1.7% and JUUL 5% Nicotine Salt Based ENDS Products, in Healthy Adult Smokers.


Description:

E-cigarettes may be an acceptable alternative to traditional cigarette smoking. In utilizing vaporization rather than combustion, the generation and inhalation of smoke and carbon monoxide (CO) may be reduced or avoided. JUUL has developed several nicotine based liquid blends for use in e-cigarettes. This study will provide an understanding of the levels of nicotine obtained with use of the company's 1.7% and 5% ENDS products.


Recruitment information / eligibility

Status Completed
Enrollment 24
Est. completion date July 26, 2018
Est. primary completion date July 26, 2018
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria: - Male or female aged 18 to 60 years of age inclusive. - Current smoker or e-cigarette user: - Able to participate, and willing to give written informed consent and to comply with the ° study restrictions. Exclusion criteria: - Clinically significant abnormality on screening ECG. - Sustained blood pressure recordings at screening of < 90 mmHg or > 150 mmHg for systolic blood pressure, or < 50 mmHg or > 90 mmHg for diastolic blood pressure. - Sustained resting heart rate of > 100 or < 40 beats per minute at screening. - Positive result for urine drugs of abuse test or alcohol breath test at screening. - Clinically significant abnormality in laboratory test results at screening, in the opinion of the Investigator. - Positive urine pregnancy test at screening or Assessment Days in female subjects of child bearing potential. - Any clinically significant concomitant disease or conditions.

Study Design


Intervention

Other:
Tobacco flavored JUUL 1.7% ENDS
Treatment with Tobacco flavored JUUL 1.7% ENDS (10 puffs)
Tobacco flavored JUUL 5% ENDS
Treatment with Tobacco flavored JUUL 5% ENDS(10 puffs)
Mint flavored JUUL 1.7% ENDS
Treatment with Mint flavored JUUL 1.7% ENDS(10 puffs)
Mint flavored JUUL 5% ENDS
Treatment with Mint flavored JUUL 5% ENDS(10 puffs)
Fruit Medley flavored JUUL 1.7% ENDS
Treatment with Fruit Medley flavored JUUL 1.7% ENDS(10 puffs)
Fruit Medley flavored JUUL 5% ENDS
Treatment with Fruit Medley flavored JUUL 5% ENDS(10 puffs)
Crème brulee flavored JUUL 1.7% ENDS
Treatment with Crème brulee flavored JUUL 1.7% ENDS(10 puffs)
Crème brulee flavored JUUL 5% ENDS
Treatment with Crème brulee flavored JUUL 5% ENDS(10 puffs)
JUUL 1.7% ENDS 10 puffs vs. ad lib puffs
Treatment with JUUL 1.7% ENDS 10 puffs vs. ad libitum puffs
JUUL 5% ENDS 10 puffs vs. ad lib puffs
Treatment with JUUL 5% ENDS 10 puffs vs. ad libitum puffs

Locations

Country Name City State
New Zealand Christchurch Clinical Studies Trust Ltd Christchurch

Sponsors (1)

Lead Sponsor Collaborator
Juul Labs, Inc.

Country where clinical trial is conducted

New Zealand, 

Outcome

Type Measure Description Time frame Safety issue
Primary Compare nicotine pharmacokinetics(PK) in smokers and e-cigarette users measuring Time to Maximum Concentration(Tmax) Compare nicotine pharmacokinetics (PK) in smokers and e-cigarette users, obtained with:
Tobacco flavored JUUL 1.7% ENDS (10 puffs); Tobacco flavored JUUL 5% ENDS (10 puffs); Mint flavored JUUL 1.7% ENDS (10 puffs); Mint flavored JUUL 5% ENDS (10 puffs); Fruit Medley flavored JUUL 1.7% ENDS (10 puffs); Fruit Medley flavored JUUL 5% ENDS (10 puffs); Crème brulee flavored JUUL 1.7% ENDS (10 puffs); Crème brulee flavored JUUL 5% ENDS (10 puffs).
38 Days
Primary Compare nicotine pharmacokinetics(PK) in smokers and e-cigarette users measuring Concentration Maximum (Cmax) Compare nicotine pharmacokinetics (PK) in smokers and e-cigarette users, obtained with:
Tobacco flavored JUUL 1.7% ENDS (10 puffs); Tobacco flavored JUUL 5% ENDS (10 puffs); Mint flavored JUUL 1.7% ENDS (10 puffs); Mint flavored JUUL 5% ENDS (10 puffs); Fruit Medley flavored JUUL 1.7% ENDS (10 puffs); Fruit Medley flavored JUUL 5% ENDS (10 puffs); Crème brulee flavored JUUL 1.7% ENDS (10 puffs); Crème brulee flavored JUUL 5% ENDS (10 puffs).
38 Days
Primary Compare nicotine pharmacokinetics(PK) in smokers and e-cigarette users measuring Cmax-baseline and Area Under the Curve ( AUC) 1hour Compare nicotine pharmacokinetics (PK) in smokers and e-cigarette users, obtained with:
Tobacco flavored JUUL 1.7% ENDS (10 puffs); Tobacco flavored JUUL 5% ENDS (10 puffs); Mint flavored JUUL 1.7% ENDS (10 puffs); Mint flavored JUUL 5% ENDS (10 puffs); Fruit Medley flavored JUUL 1.7% ENDS (10 puffs); Fruit Medley flavored JUUL 5% ENDS (10 puffs); Crème brulee flavored JUUL 1.7% ENDS (10 puffs); Crème brulee flavored JUUL 5% ENDS (10 puffs).
38 Days
Primary Compare nicotine pharmacokinetics(PK) in smokers and e-cigarette users measuring AUC1hour-baseline of nicotine Compare nicotine pharmacokinetics (PK) in smokers and e-cigarette users, obtained with:
Tobacco flavored JUUL 1.7% ENDS (10 puffs); Tobacco flavored JUUL 5% ENDS (10 puffs); Mint flavored JUUL 1.7% ENDS (10 puffs); Mint flavored JUUL 5% ENDS (10 puffs); Fruit Medley flavored JUUL 1.7% ENDS (10 puffs); Fruit Medley flavored JUUL 5% ENDS (10 puffs); Crème brulee flavored JUUL 1.7% ENDS (10 puffs); Crème brulee flavored JUUL 5% ENDS (10 puffs).
38 Days
Secondary Change in Pre and Post exhaled carbon monoxide (CO) values for each subject and Test Product. Change in Pre and Post exhaled carbon monoxide (CO) values for each subject and Test Product. 38 Days
Secondary To compare user satisfaction measures of each Test Product when consumed by smokers and e-cigarette users. Measure of subjective product evaluation using the "modified Product Evaluation Scale (mPES)" Change in Evaluation; Scale: 1 = not at all, 2 = very little, 3 = a little, 4 = moderately, 5 = a lot, 6 = quite a lot, 7 = extremely
Four multi-item subscales will be derived from "Satisfaction" (items 1, 2, 3, and 12); "Psychological Reward" (items 4 through 8); "Aversion" (items 9, 10, 16, and 18); and "Relief" (item 11, 13, 14, 15, and reversed for item 19) and single items 17 and 20 will be summarized.
38 Days
See also
  Status Clinical Trial Phase
Recruiting NCT05176418 - IV Pulsed-Nicotine as a Model of Smoking: The Effects of Dose and Delivery Rate Early Phase 1
Completed NCT04084210 - Impact of Alternative Nicotine-Delivery Products on Combustible Cigarette Use Phase 2
Completed NCT04043728 - Addressing Psychological Risk Factors Underlying Smoking Persistence in COPD Patients: The Fresh Start Study N/A
Withdrawn NCT03707600 - State and Trait Mediated Response to TMS in Substance Use Disorder N/A
Recruiting NCT03999099 - Targeting Orexin to Treat Nicotine Dependence Phase 1
Completed NCT03847155 - Prevention of Nicotine Abstinence in Critically Ill Patients After Major Surgery N/A
Completed NCT02840435 - Study on Sit to Quit Phone Intervention N/A
Completed NCT02139930 - Project 2: Strategies for Reducing Nicotine Content in Cigarettes N/A
Completed NCT01926626 - Evaluation of Moclobemide, a Reversible MAO-A Inhibitor, as an Adjunct to Nicotine Replacement Therapy in Female Smokers Phase 2
Completed NCT01982110 - A Mindfulness Based Application for Smoking Cessation N/A
Withdrawn NCT01569477 - Striving to Quit-Wisconsin Tobacco Quit Line N/A
Completed NCT01685996 - Zonisamide Augmentation of Varenicline Treatment for Smoking Cessation Phase 1/Phase 2
Completed NCT01632189 - The Effect of Varenicline on D2/D3 Receptor Binding in Smokers N/A
Completed NCT01569490 - Striving to Quit: First Breath N/A
Active, not recruiting NCT01182766 - New Treatment for Alcohol and Nicotine Dependence Phase 2/Phase 3
Completed NCT00996034 - Nicotine Vaccination and Nicotinic Receptor Occupancy Phase 2
Completed NCT01061528 - Coping Skills Treatment for Smoking Cessation N/A
Completed NCT01943994 - Psilocybin-facilitated Smoking Cessation Treatment: A Pilot Study N/A
Suspended NCT01636336 - Effects of Progesterone on Smoked Nicotine Induced Changes in Hormones and Subjective Ratings of Stimulant Drug Effects N/A
Withdrawn NCT01589081 - Effects of Progesterone on IV Nicotine-Induced Changes in Hormones and Subjective Ratings of Stimulant Drug Effect N/A